| Literature DB >> 33850748 |
Abstract
BACKGROUND: Positive surgical margins (PSM) is one of the most important factors affecting the prognosis of prostate cancer (PCa) patients after radical prostatectomy (RP). Although some studies have found the preoperative systematic inflammation-based scores the neutrophil-to-lymphocyte ratio (NLR), the platelet-to-lymphocyte ratio (PLR), lymphocyte-to-monocyte ratio (LMR) can predict the incidence and prognosis of PCa, few studies have explored the predictive value of preoperative systematic inflammation-based scores on the PSMs for PCa patients after RP.Entities:
Keywords: Prostate cancer (PCa); lymphocyte-to-monocyte ratio (LMR); positive surgical margins (PSM)
Year: 2021 PMID: 33850748 PMCID: PMC8039621 DOI: 10.21037/tau-20-1447
Source DB: PubMed Journal: Transl Androl Urol ISSN: 2223-4683
Association between individual categorical and continuous variables with positive surgical margins
| Variables | Population (n=497) | Surgical margin | P value | |
|---|---|---|---|---|
| Negative (n=230; 46.3%) | Positive (n=267; 53.7%) | |||
| Age, years, median (IQR) | 68 [63–73] | 68 [63–72] | 67 [63–73] | 0.904 |
| BMI, kg/m2, median (IQR) | 25.14 (23.5–27) | 24.97 (23.53–26.83) | 25.2 (23.38–27.16) | 0.442 |
| Diabetes, (%) | 0.238 | |||
| Absent | 420 (84.5) | 191 (83.0) | 229 (85.8) | |
| Present | 77 (15.5) | 39 (17.0) | 38 (14.2) | |
| Hypertension, (%) | 0.503 | |||
| Absent | 254 (51.1) | 118 (51.3) | 136 (50.9) | |
| Present | 243 (48.9) | 112 (48.7) | 131 (49.1) | |
| Coronary heart disease, no. (%) | 0.458 | |||
| Absent | 402 (80.9) | 187 (81.3) | 215 (80.5) | |
| Present | 95 (19.1) | 43 (18.7) | 52 (19.5) | |
| PSA, (%) | <0.001* | |||
| <20 ng/mL | 314 (63.2) | 179 (77.8) | 135 (50.6) | |
| ≥20 ng/mL | 183 (36.8) | 51 (22.2) | 132 (49.4) | |
| Serum albumin, g/L, median (IQR) | 44.7 (41.7–47.2) | 44.56 (42–47.05) | 44.8 (41.4–47.5) | 0.795 |
| Serum neutrophil, 109/L, median (IQR) | 3.6 (2.98–4.42) | 3.58 (2.98–4.4) | 3.6 (2.99–4.46) | 0.896 |
| Serum lymphocyte,109/L, median (IQR) | 1.79 (1.44–2.27) | 1.78 (1.37–2.26) | 1.79 (1.47–2.27) | 0.132 |
| Serum monocyte, 109/L, median (IQR) | 0.37 (0.31–0.45) | 0.38 (0.3–0.45) | 0.37 (0.31–0.46) | 0.828 |
| Serum platelet, 109/L, median (IQR) | 202 [171–240] | 203.5 (170.5–243.5) | 201 [172–239] | 0.768 |
| NLR, median (IQR) | 2 (1.53–2.7) | 2.05 (1.54–2.83) | 1.94 (1.51–2.6) | 0.437 |
| PLR, median (IQR) | 113 (89.81–147.01) | 118.4 (90.87–157.25) | 109.5 (89.45–138.82) | 0.111 |
| LMR, median (IQR) | 4.8 (3.86–5.97) | 4.54 (3.78–5.58) | 5 (4.02–6.08) | 0.072 |
| Prognostic nutritional index, median (IQR) | 53.85 (50.45–57.13) | 53.4 (50.34–56.95) | 53.59 (50.5–57.35) | 0.461 |
| Biopsy Gleason sum, n (%) | <0.001* | |||
| <8 | 292 (58.8) | 155 (67.4) | 137 (51.3) | |
| ≥8 | 205 (41.2) | 75 (32.6) | 130 (48.7) | |
| Perineural invasion, n (%) | <0.001* | |||
| Absent | 375 (75.5) | 197 (85.7) | 178 (66.7) | |
| Present | 122 (24.5) | 33 (14.3) | 89 (33.3) | |
| SVI, n (%) | <0.001* | |||
| Absent | 414 (83.3) | 211 (91.7) | 203 (76.4) | |
| Surgical approach, n (%) | ||||
| ORP | 28 (5.6) | 14 (50.0) | 14 (50.0) | 0.415 |
| LRP | 469 (94.4) | 216 (46.1) | 253 (53.9) | |
| Present | 83 (16.7) | 19 (8.3) | 64 (23.6) | |
| Pathologic stage | ||||
| Organ confined: pT1/pT2, no. (%) | 211 (42.4) | 211 (91.7) | 0 | |
| Non-organ confined: pT3a, no. (%) | 200 (40.2) | 0 | 200 (74.9) | |
| Non-organ confined: pT3b, no. (%) | 78 (15.7) | 19 (8.3) | 59 (22.1) | |
| Non-organ confined: pT4, no. (%) | 8 (1.7) | 0 | 8 (4) | |
| Pathologic Gleason sum, no. (%) | <0.001* | |||
| <8 | 308 (62.0) | 176 (76.5) | 132 (49.4) | |
| ≥8 | 189 (38.0) | 54 (23.5) | 135 (50.6) | |
| Location of PSM, no. (%) | ||||
| Any | 267 (53.7) | 267 (100.0) | ||
| Apical | 185 (37.2) | 185 (69.3) | ||
| Peripheral | 116 (23.3) | 116 (23.3) | ||
| Proximal | 92 (18.5) | 92 (34.5) | ||
| Number of PSM, no. (%) | ||||
| Focal positive (single) | 158 (31.8) | 158 (59.2) | ||
| Multifocal positive (more than 1) | 109 (21.9) | 109 (40.8) | ||
*, statistically significant. BMI, body mass index; PSA, prostate specific antigen; NLR, neutrophil to lymphocyte ratio; PLR, platelets to lymphocyte ratio; LMR, lymphocyteto monocyte ratio; SVI, seminal vesicle invasion; ORP, open radical prostatectomy.
Univariate and Multivariate analysis for positive surgical margins
| Variables | Univariate analysis | Multivariate analysis | |||||
|---|---|---|---|---|---|---|---|
| OR | 95% CI | P value | OR | 95% CI | P value | ||
| Age | 0.998 | 0.973–1.025 | 0.904 | ||||
| BMI | 1.025 | 0.963–1.091 | 0.441 | ||||
| PSA | 3.432 | 2.317–5.083 | <0.001* | 2.817 | 1.836–4.32 | <0.001* | |
| NLR | 0.952 | 0.841–1.078 | 0.44 | ||||
| PLR | 0.997 | 0.994–1.001 | 0.116 | ||||
| LMR | 1.086 | 0.992–1.189 | 0.074 | 1.124 | 1.018–1.24 | 0.021* | |
| Prognostic nutritional index | 1.013 | 0.979–1.047 | 0.46 | ||||
| Biopsy Gleason sum (≥8 | 1.961 | 1.361–2.826 | <0.001* | 0.902 | 0.566–1.439 | 0.665 | |
| Perineural invasion | 2.985 | 1.907–4.672 | <0.001* | 2.672 | 1.649–4.33 | <0.001* | |
| SVI | 3.501 | 2.026–6.051 | <0.001* | 1.778 | 0.96–3.29 | 0.067 | |
| Pathologic Gleason sum (≥8 | 3.333 | 2.261–4.913 | <0.001* | 2.52 | 1.556–4.082 | <0.001* | |
*, statistically significant. BMI, body mass index; PSA, prostate specific antigen; NLR, neutrophil to lymphocyte ratio; PLR, platelets to lymphocyte ratio; LMR, lymphocyteto monocyte ratio; SVI, seminal vesicle invasion.
Univariate and multivariate analysis for apical PSMs
| Variables | Univariate analysis | Multivariate analysis | |||||
|---|---|---|---|---|---|---|---|
| OR | 95% CI | P value | OR | 95% CI | P value | ||
| Age | 1.039 | 1.001–1.078 | 0.043* | 1.036 | 0.998–1.076 | 0.062 | |
| BMI | 1.001 | 0.913–1.099 | 0.977 | ||||
| PSA | 0.73 | 0.433–1.230 | 0.237 | ||||
| NLR | 1.085 | 0.888–1.325 | 0.424 | ||||
| PLR | 1.004 | 0.998–1.009 | 0.219 | ||||
| LMR | 0.875 | 0.775–0.988 | 0.031* | 0.881 | 0.779–0.996 | 0.043* | |
| Prognostic nutritional index | 1.001 | 0.954–1.050 | 0.963 | ||||
| Biopsy Gleason sum (≥8 | 0.805 | 0.478–1.355 | 0.415 | ||||
| Perineural invasion | 1.052 | 0.606–1.827 | 0.857 | ||||
| SVI | 0.91 | 0.505–1.638 | 0.753 | ||||
| Pathologic Gleason sum (≥8 | 0.963 | 0.572–1.620 | 0.886 | ||||
*, statistically significant. BMI, body mass index; PSA, prostate specific antigen; NLR, neutrophil to lymphocyte ratio; PLR, platelets to lymphocyte ratio; LMR, lymphocyteto monocyte ratio; SVI, seminal vesicle invasion.
Univariate and Multivariate analysis for peripheral PSMs
| Variables | Univariate analysis | Multivariate analysis | |||||
|---|---|---|---|---|---|---|---|
| OR | 95% CI | P value | OR | 95% CI | P value | ||
| Age | 0.975 | 0.941–1.009 | 0.144 | ||||
| BMI | 0.946 | 0.867–1.032 | 0.213 | ||||
| PSA | 1.926 | 1.179–3.145 | 0.009* | 2.029 | 1.226–3.357 | 0.006* | |
| NLR | 1.039 | 0.891–1.212 | 0.625 | ||||
| PLR | 0.996 | 0.991–1.001 | 0.13 | ||||
| LMR | 1.123 | 0.997–1.265 | 0.057 | 1.128 | 0.999–1.275 | 0.053 | |
| Prognostic nutritional index | 0.993 | 0.950–1.039 | 0.768 | ||||
| Biopsy Gleason sum (≥8 | 1.401 | 0.862–2.278 | 0.173 | ||||
| Perineural invasion | 1.962 | 1.173–3.281 | 0.01* | 1.934 | 1.143–3.274 | 0.014* | |
| SVI | 1.456 | 0.840–2.526 | 0.181 | ||||
| Pathologic Gleason sum (≥8 | 1.387 | 0.853–2.254 | 0.187 | ||||
*, statistically significant. BMI, body mass index; PSA, prostate specific antigen; NLR, neutrophil to lymphocyte ratio; PLR, platelets to lymphocyte ratio; LMR, lymphocyteto monocyte ratio; SVI, seminal vesicle invasion.
Univariate and Multivariate analysis for proximal PSMs
| Variables | Univariate analysis | Multivariate analysis | |||||
|---|---|---|---|---|---|---|---|
| OR | 95% CI | P value | OR | 95% CI | P value | ||
| Age | 0.99 | 0.955–1.026 | 0.568 | ||||
| BMI | 0.979 | 0.894–1.072 | 0.644 | ||||
| PSA | 1.651 | 0.992–2.749 | 0.054 | 1.436 | 0.847–2.433 | 0.179 | |
| NLR | 1.018 | 0.870–1.191 | 0.826 | ||||
| PLR | 0.999 | 0.994–1.003 | 0.556 | ||||
| LMR | 1.084 | 0.965–1.218 | 0.173 | ||||
| Prognostic nutritional index | 0.995 | 0.950–1.043 | 0.846 | ||||
| Biopsy Gleason sum (≥8 | 1.414 | 0.852–2.346 | 0.181 | ||||
| Perineural invasion | 0.86 | 0.502–1.474 | 0.584 | ||||
| SVI | 2.413 | 1.373–4.240 | 0.002* | 2.052 | 1.124–3.746 | 0.019* | |
| Pathologic Gleason sum (≥8 | 1.765 | 1.058–2.945 | 0.03* | 1.329 | 0.762–2.317 | 0.316 | |
*, statistically significant. BMI, body mass index; PSA, prostate specific antigen; NLR, neutrophil to lymphocyte ratio; PLR, platelets to lymphocyte ratio; LMR, lymphocyteto monocyte ratio; SVI, seminal vesicle invasion.
Figure 1ROC curves in predicting apex PSMs by LMR (continuous, AUC =0.557). ROC receiver operating characteristic, AUC area under the curve.
Univariate and Multivariate analysis for focal PSMs
| Variables | Univariate analysis | Multivariate analysis | |||||
|---|---|---|---|---|---|---|---|
| OR | 95% CI | P value | OR | 95% CI | P value | ||
| Age | 1.001 | 0.971–1.032 | 0.961 | ||||
| BMI | 1.052 | 0.979–1.132 | 0.168 | ||||
| PSA | 2.721 | 1.748–4.235 | <0.001* | 2.374 | 1.482–3.803 | <0.001* | |
| NLR | 0.857 | 0.712–1.031 | 0.102 | ||||
| PLR | 0.998 | 0.995–1.002 | 0.359 | ||||
| LMR | 1.065 | 0.964–1.178 | 0.217 | ||||
| Prognostic nutritional index | 1.024 | 0.982–1.067 | 0.272 | ||||
| Biopsy Gleason sum (≥8 | 1.73 | 1.140–2.626 | 0.01* | 0.966 | 0.571–1.635 | 0.897 | |
| Perineural invasion | 2.452 | 1.482–4.057 | <0.001* | 2.349 | 1.381–3.995 | 0.002* | |
| SVI | 2.714 | 1.487–4.955 | 0.001* | 1.566 | 0.796–3.079 | 0.194 | |
| Pathologic Gleason sum (≥8 | 2.4 | 1.547–3.721 | <0.001* | 1.780 | 1.032–3.076 | 0.039 | |
*, statistically significant. BMI, body mass index; PSA, prostate specific antigen; NLR, neutrophil to lymphocyte ratio; PLR, platelets to lymphocyte ratio; LMR, lymphocyteto monocyte ratio; SVI, seminal vesicle invasion.
Univariate and Multivariate analysis for multifocal PSMs
| Variables | Univariate analysis | Multivariate analysis | |||||
|---|---|---|---|---|---|---|---|
| OR | 95% CI | P value | OR | 95% CI | P value | ||
| Age | 0.99 | 0.962–1.029 | 0.772 | ||||
| BMI | 0.979 | 0.913–1.069 | 0.764 | ||||
| PSA | 1.651 | 2.947–7.856 | <0.001* | 3.5 | 1.993–6.147 | <0.001* | |
| NLR | 1.018 | 0.884–1.173 | 0.799 | ||||
| PLR | 0.999 | 0.991–1.000 | 0.06 | ||||
| LMR | 1.084 | 0.996–1.256 | 0.059 | 1.179 | 1.023–1.358 | 0.023* | |
| Prognostic nutritional index | 0.995 | 0.961–1.044 | 0.936 | ||||
| Biopsy Gleason sum (≥8 | 1.414 | 1.474–3.747 | <0.001* | 6.867 | 0.461–1.630 | 0.658 | |
| Perineural invasion | 4.04 | 2.375–6.875 | <0.001* | 3.446 | 1.863–6.372 | <0.001* | |
| SVI | 4.822 | 2.588–8.985 | <0.001* | 2.064 | 0.991–4.298 | 0.053 | |
| Pathologic Gleason sum (≥8 | 5.406 | 3.301–8.851 | <0.001* | 3.931 | 2.078–7.436 | <0.001* | |
*, statistically significant. BMI, body mass index; PSA, prostate specific antigen; NLR, neutrophil to lymphocyte ratio; PLR, platelets to lymphocyte ratio; LMR, lymphocyteto monocyte ratio; SVI, seminal vesicle invasion.